Our initial focus on clinical research is to provide legal supply to patients with Drug Resistant Epilepsy (DRE) to access our phytocannabinoid treatment EP1, approved for patients for the treatment of drug resistant epilepsy in Israel.
EP1 is a CBD enriched sublingual treatment that has been through a two year federally endorsed clinical trial – one of few phytocannabinoid CBD intensive products – demand for the product in overseas markets is far outstripping supply.
Cann Pharma has a multi-pillar strategy to fast track legal supply of EP1 in Australia.
We also have a deep pipeline of additional cannabinoid product candidates which includes epilepsy, autism, a number of cancers, pain and neurological conditions caused by damage to the central nervous system (CNS) and terminal illnesses.
Our melanoma clinical studies are aimed at developing a combination treatment for patients that are not responders to check point immune inhibitors such as PD-1/PD-L1. Over 50% of these patients show progression of cancer recurrence.
Melanoma has increased in incidence faster than any other cancer type since the mid-1950s. Melanoma is the most common cancer in young Australians (15-39 year olds).
Our drug discovery and development process pipeline extends to other cancers where patients are refractory to current therapeutic treatment.
If you are interested in working with Cann Pharma regarding specific investigator initiated pre-clinical and clinical research, please contact Cann Pharma via email.